Rezolute announces proposed public offering of common stock and pre-funded warrants

New york, june 13, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). in addition, the company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. the public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. all of the shares in the public offering are being offered by the company.
RZLT Ratings Summary
RZLT Quant Ranking